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Abstract
In Genetic Analysis Workshop 18 data, we used a 3-stage approach to explore the benefits of pathway analysis in
improving a model to predict 2 diastolic blood pressure phenotypes as a function of genetic variation. At stage 1,
gene-based tests of association in family data of approximately 800 individuals found over 600 genes associated at
p<0.05 for each phenotype. At stage 2, networks and enriched pathways were estimated with Cytoscape for genes
from stage 1, separately for the 2 phenotypes, then examining network overlap. This overlap identified 4 enriched
pathways, and 3 of these pathways appear to interact, and are likely candidates for playing a role in hypertension.
At stage 3, using 157 maximally unrelated individuals, partial least squares regression was used to find associations
between diastolic blood pressure and single-nucleotide polymorphisms in genes highlighted by the pathway
analyses. However, we saw no improvement in the adjusted cross-validated R2. Although our pathway-motivated
regressions did not improve prediction of diastolic blood pressure, merging gene networks did identify several
plausible pathways for hypertension.
Background
Pathway analysis of results from genetic association stu-
dies has become a very popular approach, and usually the
goal is to gain a better understanding of which genes or
groups of genes are related to the disease or trait being
studied. However, “a better understanding” is not usually
well defined. We chose to investigate whether pathway
analysis could improve the R2 value in a partial least
squares (PLS) regression model predicting phenotype as
a function of single-nucleotide polymorphisms (SNPs).
Our hypothesis was that pathway analysis would high-
light genes containing many SNPs with effects too small
to be detected in univariate analyses, but that the PLS
components (or latent variables) might benefit from such
signals.
Analyses used a multistage approach to analyze asso-
ciations with diastolic blood pressure (DBP) in the
Genetic Analysis Workshop 18 (GAW18) data. At stage
1, we tested for association between sequence variation
in each gene and DBP in the families. At stage 2, we built
gene networks from the significant genes identified in
stage 1, using Cytoscape [1-3] and identified enriched
pathways. Stage 3 included the PLS regression models on
unrelated individuals using different sets of SNPs moti-
vated by stages 1 and 2.
Methods
Phenotype
We used 2 different DBP phenotypes: DBP at the first
visit (DBP-1) and a measure of DBP change with age
(DBP-C). In the GAW18 dataset, 795 individuals had
both a DBP-1 measurement and genotype information;
no covariates were used when analysing DBP-1. Slopes of
DBP versus age were estimated from only 2 to 4 mea-
surements in each of 855 individuals, and then slopes
were adjusted for smoking and antihypertensive medica-
tion use, and categorized into 3 levels: none of the visits,
some visits, or all visits. The resulting residuals formed
our second phenotype, measuring whether an individual’s
blood pressure changes more or less than the average.
There were 611 individuals with DBP-C and genotype
information.
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Stage 1: ASKAT
Gene-based tests of association between the exome
sequencing data and the DBP-1 and DBP-C phenotypes
were performed using ASKAT [4], a method for quantita-
tive phenotype analysis in families developed by our
group. ASKAT fits a linear mixed model adjusting for the
relationships by using the estimated kinship matrix.
Kinship matrices were calculated for each odd-numbered
chromosome using the genotype data in the chrx-geno.
csv files. SNPs with minor allele frequency less than 0.01
were removed, and the kinship matrices were calculated
using GenABEL v1.7-0 [5]. The average of all odd-
numbered chromosome-specific kinship matrices was
used in the gene-based ASKAT tests. Gene names were
retrieved from hg19 build 37 (http://genome.ucsc.edu)
[6], and we tested association between sequence-derived
genetic variation (from the chrx-dose.csv files) in the
exons of each gene and the DBP-1 and DBP-C pheno-
types, using a total of 147,103 genetic variants. To opti-
mize power to detect rare variants, the 201 genes
containing more than 50 variants were divided into a ser-
ies of non-overlapping windows with a maximum of
50 variants per window (based on empirical data from
our group, not shown). For such genes, the minimum
p value summarized the gene result.
Stage 2: Pathway analysis
For DBP-1 and DBP-C, network analysis was performed
using methods in Cytoscape 2.8.2 [7,8]. Networks were
built using “Reactome FI” on genes with p value ≤0.05
from stage 1. The networks for DBP-1 and DBP-C were
then compared and merged using “Advanced Network
Merge-Intersection.” Pathway analysis for genes in com-
mon was performed using the “Analyze Module Function.”
Stage 3: Regression analysis
PLS regression analysis was used for prediction modeling
of our 2 phenotypes as a function of the number of
minor alleles in SNPs identified by stages 1 and 2. PLS
searches for multidimensional linear combinations of
SNPs that explain the maximum variance direction of the
phenotype, and can be thought of as constructing latent
predictor variables. PLS models, using plsr version 2.3-0
of library pls [9], were fit to the 157 maximally unrelated
individuals, using all variants from the chrx-dose.csv files,
located in the genes identified by (a) p value ≤0.05 in
gene-based analyses from stage 1, (b) stage 2 enriched
pathways for DBP-1 or DBP-C with a false discovery rate
(FDR) ≤0.05, or (c) stage 2 enriched pathways in the
overlapping gene network. Tenfold cross-validation was
used to choose the optimal number of PLS components,
and we report the number of PLS components that gave
the smallest adjusted cross-validated R2.
Results
Stage 1: ASKAT analysis
After analysis of 10,744 genes with ASKAT, 601 genes
showed significant association with the DBP-1 phenotype
(p value ≤0.05), whereas 694 genes were significant for the
DBP-C phenotype. Among the 20 lowest p values for each
phenotype, there were no genes in common (Table 1).
The minimum p values were 6.31 × 10−5 and 6.08 × 10−6
for DBP-1 and DBP-C, respectively.
Stage 2: Pathway analysis
We found 84 enriched pathways (51 different genes)
with FDR ≤0.05 for DBP-1, and 88 for DBP-C (59 differ-
ent genes). There were 26 enriched pathways in com-
mon, but only the cadherin signalling pathway (P) and
G2/M pathway (R) were part of the top 20 enriched
pathways for both phenotypes. Merging the networks
from the 2 phenotypes revealed some gene networks in
common (Figure 1) containing 17 genes, and we esti-
mated pathway enrichment in this set, finding 4 path-
ways that were enriched with FDR ≤0.05 (Table 2).
Stage 3-Regression analysis
Table 3 (fourth column) shows the optimal number of
PLS components, identified by cross-validation, for the 2
phenotypes and for the 3 strategies for selecting SNPs.
This approach identified either no components (linear
combinations of SNPs) or 1 PLS component as provid-
ing the best fit to explain phenotype. However, even
when 1 component was chosen as best, the improve-
ment in error over the model with no components was
minimal. To explore these results a bit differently, we
measured the contribution per SNP for a 1-component
PLS model, dividing the model R2 by the number of
SNPs in the PLS component that had nonzero regres-
sion coefficient (Table 3, last column). It can be seen
that the pathway approaches improve this per-SNP con-
tribution to R2. Also, the improvement in SNP impor-
tance across the 3 strategies is similar for either
phenotype.
Table 1 Ten most significant genes from stage 1, ASKAT,
with p values
DPB-1 OSBPL3 GOBP1 HECW1 ZNF589 PARP1
6.31 × 10−5 7.21 × 10−5 0.000138 0.000299 0.000361
CCDC136 PLXDC1 NMUR2 C7orf69 LOC285954
0.000372 0.000389 0.000412 0.000494 0.000796
DBP-C C3orf24 TSR1 PEF1 NFP1P1 TESSP2
6.08 × 10−6 1.11 × 10−5 4.71 × 10−5 0.000109 0.000109
ISLR2 YWHAG C15orf37 ZNF281 OR10H3
0.0002 0.000201 0.000251 0.000299 0.00036
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Discussion
Our pathway analysis was performed with Cytoscape,
which is one among many possible pathway analysis tools.
We also tried Gene Set Enrichment Analysis (GSEA)
using the JAVA applet GSEA software v2.07 from the
Broad Institute [10]. GSEA takes into account the gene
rank, and tests whether a pathway is enriched by looking
for an overrepresentation of genes at the top or bottom of
a ranked list of p values. Using this method, no enriched
pathway had FDR ≤0.05. However, a study comparing
gene-set enrichment tests reported that GSEA was more
consistent in finding enriched pathways [11].
Pathway analysis is often heralded as a solution for
better understanding genetic effects, but how to best
benefit from it is unclear. We selected a definition,
improvement in R2 of a multivariate (PLS) regression
model, which is one of many possible definitions, and
we explored this in GAW18 DBP data. We selected PLS
regression in order to optimize construction of latent
predictors, but the optimal number of PLS components
identified through cross-validation was often zero for
either phenotype and for any of the 3 gene and pathway
selection strategies. We did not, in fact, find evidence
for improved prediction of DBP using our strategy.
However, PLS was not designed for categorical data and
may not be the best choice for capturing associations
between numerous SNPs and phenotype. When we
forced a PLS fit with 1 component, the per-SNP contri-
butions to R2 from the overlapping genes were larger
than when we used other approaches. It must be noted
that although stage 1 used family data and stage 3 used
unrelated individuals data, there is some overlap
between these sets of individuals, and hence the per-
SNP improvement in Table 3 may be partially explained
by model over-fitting.
We chose to work with 2 DBP phenotypes, DBP at
first visit, and a measure of DBP change with age. In
most individuals, blood pressure increases with age. Our
DBP-C phenotype, the residuals from a regression on
age, measures each individual’s sensitivity to the factors
that lead to this general population trend of increasing
DBP with age. We adjusted for medication use and
smoking in a second model because with only 2 to 4
measurements per person, full longitudinal modeling
was not possible. In this work, we have not adjusted for
Figure 1 Pathway analysis results. Networks in common between the significant gene lists for DBP-1 and DBP-C. The size of the circle is
inversely related to the gene’s p value.
Table 2 Pathways enriched in overlapping networks of
genes associated with DBP-1 and DBP-C
Pathway name Gene name p Value FDR
Cadherin Signalling Pathway (P) PCDH9, PCDHAC2 0.003 0.004
Wnt Signalling Pathway (P) PCDH9, PCDHAC2 0.018 0.0425
Integrin Signalling Pathway (P) COL16A1, FLNC 0.008 0.025
G2/M Transition (R) TUBGCP4, YWHAG 0.001 0.005
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the variable precision of the slope estimates or age for
DBP-1, and we recognize that this is a limitation.
Because our 2 phenotypes (DBP-1 and DBP-C) are clo-
sely related, we decided to focus our pathway analysis on
gene networks present for both phenotypes. This strategy
led to identification of 4 pathways significantly associated
with DBP-1 and DBP-C. The first 3 pathways (see Table 2)
interact together and play a role in pathogenesis of hyper-
tension [12,13]. The G2/M transition pathway is known to
be affected by leptin [14], a protein associated with hyper-
tension [15].
Only odd-numbered chromosomes were included in
GAW18, thus our identified pathways and networks will
be incomplete. An analysis of the entire genome might
validate our findings and provide additional significant
associations. Furthermore, Cytoscape only assigned
pathways to 120 genes out of the approximately 600
selected for either phenotype, thus providing further
motivation to continue our analysis of a larger curated
set of genes in pathways. Despite all the caveats in this
work, it is interesting that our approach of examining
overlapping pathways identified 3 pathways that are
plausibly related to hypertension.
Conclusions
For DBP or DBP changes in GAW18 data, we exam-
ined whether using pathway analysis results improved
R2 in multivariate regression models. Although we did
not find evidence for improved model fits, 3 enriched
pathways contained plausible hypertension-related
genes.
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